TempraMed Strengthens Global Intellectual Property Position with Grant of South Korean Patent
Highlights Newly granted patent protects TempraMed's VIVI Box™ proprietary, hassle-free thermal-insulation system and smart-monitoring architecture Expands the Company's ability to adapt its core technology to a wider range of drug categories-from chronic self-injectables to complex biologics Enhances commercialization opportunities and supports strategic engagement with leading appliance manufacturers in
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-15 5:00 PM EST | TempraMed Technologies Ltd
Apyron Pioneering Next Generation Pain Management Solutions
Atlanta, Georgia--(Newsfile Corp. - December 15, 2025) - Apyron, Inc. is a medical technology company with a product portfolio designed to address chronic pain and joint-related disorders, with a core value to restore mobility in patients and provide them agency over their therapy. Apyron's product portfolio is being developed to address two major contributors to disability — chronic lower back pain and joint disease. Chronic pain markets account for over $384 million of healthcare spe
Biotechnology, Healthcare and Hospitals, Health
2025-12-15 9:00 AM EST | Apyron, Inc.
CBIH: Potential Rescheduling to Schedule III Could Reward Decades of Scientific Preparation and Regulatory Discipline
Houston, Texas--(Newsfile Corp. - December 15, 2025) - Dante Picazo, CEO of Cannabis Bioscience International Holdings, Inc. trading under ticker symbol CBIH (OTCID: CBIH), provided the following update in light of recent reports suggesting that President Donald Trump may issue an executive order aimed at accelerating the federal process of rescheduling cannabis from Schedule I to Schedule III. CBIH believes that, if the process moves forward, it could represent one of the most conseque
Biotechnology, Pharmaceuticals, Cannabis, Health
2025-12-15 7:00 AM EST | Cannabis Bioscience International Holdings
OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
FDA confirmed that data from single-arm studies in rare diseases, such as in ultra-rare deadly pediatric cancer osteosarcoma, could support a Biologics Licensing Application (BLA) under Accelerated Approval Program pathway, as stated in FDA guidance documents FDA proposed confirmatory study design include additional osteosarcoma disease settings such as prevention of recurrence following primary tumor resection, where a randomized controlled study
2025-12-15 6:00 AM EST | OS Therapies
NervGen Pharma Announces Proposed Amendment to Warrants
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) ("NervGen" or the "Company"), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders, today announced that the Company intends to amend 5,075,000 common share purchase warrants (the "2022 Warrants") that were issued pursuant to a private placement of units that c
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-12-12 7:51 PM EST | NervGen Pharma Corp.
InMed Provides Update on BayMedica Commercial Business
Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement. Recently, H.R. 5371, the "Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extension
Biotechnology, Pharmaceuticals
2025-12-12 5:31 PM EST | InMed Pharmaceuticals
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, has commenced a non-brokered private placement of units of the Company ("Units") to raise up to $CAN 2,000,000 (&#
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2025-12-12 5:00 PM EST | Theralase Technologies Inc.
Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting
Toronto, Ontario--(Newsfile Corp. - December 11, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the company highlighted its approach to Multiple Myeloma (MM) Minimal Residual Disease (MRD) testing with a poster presentation during the 67th American Society of Hematology (ASH) Annual Meeting i
2025-12-11 4:00 PM EST | Telo Genomics Corp.
Biosenta to Field-Test Antimicrobial Nanoparticles with Livespace Homes in Alberta Multi-Unit Build
Ontario and Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Biosenta Inc. (CSE: ZRO) ("Biosenta") On December 8, 2025 Biosenta has entered into a Field Test and Research Agreement with Livespace Homes to evaluate the real-world performance of Biosenta's proprietary antimicrobial nanoparticle technology in a residential construction environment. Under the agreement, the nanoparticles will be incorporated into building materials and/or coatings used in two (2) of the four (4)
Biotechnology, Chemical, Household / Consumer / Cosmetics
2025-12-11 2:21 PM EST | Biosenta Inc.
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from vascular dementia, angina, ischemic cardiomyopathy, congestive heart failure, non-ischemic dilated cardiomyopathy, pain, total body ischemia, peripheral arterial disease and chronic limb threatening ischemia, is pleased to announce that Thomas Smeenk
Biotechnology, Pharmaceuticals, Health
2025-12-11 9:40 AM EST | Hemostemix Inc.
Hemostemix Grants Stock Options
Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock option plan, it has granted on December 11, 2025, subject to regulatory approval, a total of 963,000 stock options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants of Hemostemix. Of the Options granted, 663,000 vest immediately and
Biotechnology, Pharmaceuticals, Health
2025-12-11 8:57 AM EST | Hemostemix Inc.
Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - December 10, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development, is pleased to announce that, further to its news release o
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-12-10 8:00 PM EST | Quantum BioPharma Ltd.
TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - December 10, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the appointment of Professor Dr. Lutz Heinemann, one of the world's foremost diabetes researchers, to its Scientific Advisory Board. His appointment further enhances TempraMed's scientific foundation as the Company
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-10 5:00 PM EST | TempraMed Technologies Ltd
Defence Therapeutics Announces AGM Results and Provides Corporate Updates
Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic treatments, is pleased to announce that the Shareholders approved all matters presented at the Company's annual general meeting of the shareholders held today, as follows:
Biotechnology, Pharmaceuticals, Health
2025-12-10 4:30 PM EST | Defence Therapeutics Inc.
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
Calgary, Alberta--(Newsfile Corp. - December 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from vascular dementia, angina, ischemic cardiomyopathy, congestive heart failure, non-ischemic dilated cardiomyopathy, pain, total body ischemia, peripheral arterial disease and chronic limb threatening ischemia, with ACP
Biotechnology, Pharmaceuticals, Health
2025-12-10 11:17 AM EST | Hemostemix Inc.
Envoy Medical Completes First Set of Activations in Final Stage of Pivotal Clinical Study for its First-Of-Its-Kind Fully Implanted Acclaim(R) Cochlear Implant
White Bear Lake, Minnesota--(Newsfile Corp. - December 10, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the completion of the first set of activations in the final stage of the pivotal clinical study for the investigational fully implanted Acclaim® cochlear implant. These activations were performed at Shohet Ear Associates in Seal Beach, California and the C
Biotechnology, Healthcare and Hospitals
2025-12-10 8:00 AM EST | Envoy Medical, Inc.
MustGrow Reports Significant U.S. Potato Yield and Economic Performance in Large Scale Field Trials Utilizing TerraSante(TM)
Mustard-derived organic TerraSanteTM focuses on crop yields, soil and soil microbiome health, and nutrient/water use efficiencies; Large scale field trial showed 2 ton per acre yield increase with larger size potatoes and less culls equating to approximately US$5,000 increase in value per acre; and Significant soil health benefit when applied in combination with the current grower standard program.
Agriculture, Biotechnology, Cannabis, Cannabis Breeder
2025-12-10 7:00 AM EST | MustGrow Biologics Corp.
OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
Alignment achieved on all key points surrounding non-clinical, CMC and post-market authorization confirmatory study design Biomarker data advanced as key pre-specified surrogate clinical efficacy endpoint, with pending analysis awaiting alignment with US FDA on biomarker statistical analysis plan to be discussed at upcoming December 11, 2025 FDA Type C Meeting Company reiterates end of January 2026 timeline for MAA submission N
2025-12-09 7:40 AM EST | OS Therapies
TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients
Vancouver, British Columbia--(Newsfile Corp. - December 8, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a major commercial milestone as part of its broader global expansion strategy: its flagship products, the VIVI Cap and VIVI EPI, are now available through Maccabi Healthcare Services, Israel's second-largest health
Technology, Biotechnology, Pharmaceuticals, Health
2025-12-08 5:00 PM EST | TempraMed Technologies Ltd
CellCentric Presents Positive Phase 2 Dose Optimization Data for Inobrodib in Multiple Myeloma at ASH Annual Meeting
- Inobrodib in combination with pomalidomide + dexamethasone (InoPd) demonstrates strong clinical efficacy and a tolerable safety profile in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients - - Observed response rates of 60-75% with inobrodib 20 mg and 30 mg cohorts result in clinical efficacy at least two-fold higher than previously published real-world data for pom-refractory, bispecific or anti-B
2025-12-07 8:00 AM EST | CellCentric, Inc